港股異動丨鉅子生物拉昇漲超5%,大股東計劃斥資最少2億港元增持
鉅子生物(2367.HK)午後拉昇,漲超5%,報62.2港元,截至目前成交額放大至逾14億港元。消息面上,公司公佈,接獲控股股東Juzi Holding通知,基於對公司價值的認可和對公司未來整體業務發展及增長潛力的信心,Juzi Holding計劃3-6個月內增持公司股份,增持金額不低於2億港元。Juzi Holding現持有公司股份約54.26%。若增持計劃實施,公司仍將維持足夠公衆持股量。公司董事會認爲,Juzi Holding的增持計劃反映控股股東對公司做出的長期承諾以及對公司前景的堅定信心。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.